Answers are grounded in this paper and cite their sources.
M), translated in a LUMABS sensor with a strongly attenuated sensor response. The trastuzumab and cetuximab sensors were further characterized with respect to binding kinetics and their performance in undiluted blood plasma. For both antibodies, LUMABS-based detection directly in plasma compared well to the analytical performance of commercial ELISA kits. Besides identifying important design parameters for the development of new LUMABS sensors, this work demonstrates the potential of the LUMABS platform for point-of-care detection of therapeutic antibodies.
No takes yet. Share an insight, caveat, or question.
Rosmalen et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: